Chinese clinical-stage innovative drug developer Kangpu Biopharmaceuticals unveiled on Friday that it has raised nearly RMB100 million (US$14.18 million) in a series pre-B round of financing.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!Register Now
Already have an account or paid subscription?